drugset / Trial / NCT04381988

A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

NCT04381988 ↗

Phase 2 Terminated 4 enrolled Memorial Sloan Kettering Cancer Center
RandomizedParallel-groupTriple-blindPrevention

Summary

The researchers are doing this study to find out whether the study drug hydroxychloroquine can prevent infection with the COVID-19 virus, compared with placebo, in people who are receiving radiation therapy for their cancer. The placebo used in this study is a tablet that looks the same as the study drug and is taken in the same way, but it does not contain any active ingredients.

Timeline

Start
2020-05-07
Primary completion
2021-04-21
Completion
2021-04-21

Outcome

Outcome not reported

Stopped: “The study was terminated based results of other studies and use of the new vaccine.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 400 mg —

Indications